UNASSIGNED: Transplantation of @entity361 ( @entity361 ), expanded with @entity2241 ( @entity2241 ), has some limitations, including a long culture period required to obtain sufficient stem cells. Priming of @entity361 with serum from @entity1 with @entity385 ( @entity64 serum) increased the proliferation rate and the neurorestorative capacity of @entity361 . We hypothesized that this novel priming method increases the proliferation rate of @entity361 via the regulation of microRNAs (miRs). Thus, we investigated @entity34326 profiling in @entity64 serum primed @entity361 and tested whether the regulation of certain miRs may affect the proliferation rate of @entity35 @entity361 . The proliferation rate of @entity361 cultured with @entity64 serum was higher than that of @entity361 cultured with normal serum or @entity2241 . Using @entity34326 microarray analysis, we compared the @entity34326 expression profiles between @entity361 cultured in @entity2241 and in @entity64 serum. Among miRs associated with cell proliferation, @entity69269 was most significantly increased. Similarly, @entity69269 was increased in @entity361 obtained from the bone marrow of @entity64 @entity35 compared with @entity361 from normal @entity35 . Furthermore, the deregulation of @entity69269 by the transfection of @entity361 with pre- @entity69269 or anti- @entity69269 was significantly correlated with the proliferation rate of @entity361 . The overexpression of @entity69269 in @entity361 cultured in @entity2241 improved the proliferation rate, while the knockdown of endogenous @entity69269 decreased the proliferation rate. In addition, @entity69269 promoted proliferation by suppressing the expression of @entity7504 cyclin-dependent kinase inhibitor 1 ( @entity9533 ). Dual-luciferase reporter assay showed that @entity9533 is a target of @entity69269 . Our findings indicate that @entity64 serum priming up-regulated the expression of @entity69269 , which promoted MSC proliferation by regulating the cell cycle inhibitor @entity7504 @entity9533 , and suggest the possible roles of priming methods in modulating the characteristics of @entity361 by controlling the expression of @entity34326 in @entity361 .

XXXX serum priming modulates characteristics of mesenchymal stromal cells by controlling the expression miRNA-20a.

@entity1 :: ('9606', 'Species') :: ['patients'] @entity64 :: ('MESH:D020521', 'Disease') :: ['stroke'] @entity7504 :: ('24525(Tax:10116)', 'Gene') :: ['p21'] @entity35 :: ('10116', 'Species') :: ['rat', 'rats'] @entity9533 :: ('114851(Tax:10116)', 'Gene') :: ['CDKN1A'] @entity69269 :: ('100314222(Tax:10116)', 'Gene') :: ['miR-20a'] @entity361 :: ('MESH:C535700', 'Disease') :: ['mesenchymal stem cells', 'MSCs'] @entity34326 :: ('306825(Tax:10116)', 'Gene') :: ['miR'] @entity2241 :: ('MESH:D005315', 'Disease') :: ['FBS', 'fetal bovine serum'] @entity385 :: ('MESH:D002544', 'Disease') :: ['ischemic stroke']
@entity64 :: (MESH:D020521,Disease) :: ['Stroke']
